Our History

Our History

Our History

We are proud of our rich heritage in medical innovation. The timeline below charts our transformation from a successful intellectual property commercialisation firm into a global healthcare company focused on Interventional Medicine.

Along the way we have partnered with some of the world's leading healthcare companies and played a part in bringing significant medical innovations to market.  Today our innovative medical technology helps physicians treat their patients through minimally invasive procedures.

2018 Visual-ICE MRI receives FDA 510(k) clearance and EU CE Mark certification
2017 Acquisition of Roxwood Medical, Inc; DC Bead LUMI™ receives EU CE Mark certification
2016 Acquisition of Galil Medical Inc.
2015 Acquisition of PneumRx, Inc.; LC Bead LUMI™ receives FDA 510(k) clearance
2014 Varithena® (polidocanol injectable foam) 1% launched in the US; BTG begins selling its own Interventional Oncology products in the EU.
2013 Acquisition of EKOS Corporation; Acquisition of TheraSphere®; Varithena® (polidocanol injectable foam) 1% approved in the US
2012 Voraxaze® (glucarpidase) approved and launched in the US; US and EU approve expanded Zytiga® (abiraterone acetate) indication for treatment of metastatic castration-resistant prostate cancer
2011 Acquisition of Biocompatibles International plc; Zytiga® approved in the US and EU
2010  BTG begins selling its own products in the US; DigiFab® (digoxin immune fab (ovine)) receives first European regulatory approval
2008 Acquisition of Protherics PLC 
2006 Divestment of the majority of the physical sciences IP portfolio
2005  Strategic business review leads to focus on life sciences
2003  Nobel Prize for Medicine awarded to inventor of MRI, a technology first licensed by BTG in the 1980s
2002 US launch of DigiFab®, a treatment for the toxic effects of over dosage with the heart drug digoxin
2001  US launch of CroFab® (crotalidae polyvalent immune fab (ovine)), the first new rattlesnake antivenom on the US market in 50 years; US approval of Campath® (alemtuzumab) and EU approval of MabCampath® (alemtuzumab) for chronic lymphocytic leukaemia
1997  BeneFIX® (coagulation factor IX (recombinant)) treatment for haemophilia B launched in the US
1996 Following settlement with Johnson & Johnson for the Two-Part Hip Cup patents, BTG licensed them to all major orthopaedic companies.
1995  BTG plc is listed on the London Stock Exchange (LSE:BGC (now LSE:BTG))
1992 BTG is privatised
1981 BTG is formed from the merger of the National Research & Development Council and the National Enterprise Board
1970s  Development and launch of: cholesterol assay tests; MRI; Oxford three-part knee
1960s Patenting/development of: continuously variable transmission; cephalosporin antibiotics; pyrethrin insecticides
1950s Patenting of interferon
1948 National Research Development Corporation founded by UK government to commercialise publicly funded research.